Wedgewood Releases Compounded Molnupiravir for FIP in Cats

Wedgewood, a leading veterinary compounding pharmacy in the United States, has added molnupiravir to its formulary. Originally developed to combat human viral infections such as COVID-19, molnupiravir has shown promise as both a primary and secondary treatment for Feline Infectious Peritonitis (FIP). FIP is a serious and often deadly disease that affects approximately 15,000 cats in the U.S. each year, making it a significant concern for veterinarians and cat owners.

Wedgewood stands out as the first veterinary compounding pharmacy in the U.S. to offer molnupiravir in feline-friendly formulations. These include a variety of doses specifically tailored to address the different types of FIP, such as Effusive, Non-effusive, Neurological, and Ocular forms. Available formulations include:
- Flavored Oral Oil Suspensions in 50mg/ml and 100mg/ml
- Capsules in 25mg, 40mg, 50mg, 60mg, 70mg, and 80mg dosages

In late 2023, Wedgewood's product team collaborated with FIP Global Cats to investigate various treatment options for FIP. This collaboration was spurred by two key studies highlighting the effectiveness of molnupiravir. One study by Dr. Okihiro Sase of the You-Me Animal Clinic in Japan reported significant remission in the majority of 18 cats treated with molnupiravir, with minimal side effects. Another study by researchers including Meagan Roy, Nicole Jacque, Wendy Novicoff, Emma Li, Rosa Negash, and Samantha J. M. Evans also emphasized molnupiravir's potential as both a primary and rescue treatment for FIP. However, Wedgewood clarifies that its formulation of molnupiravir is different from the drug used in these studies and does not claim its version's safety or efficacy.

Dr. Alejandro Bernal, CEO of Wedgewood, discussed the importance of this development: "At Wedgewood, we strive to introduce innovative treatment options that make a significant impact. The introduction of molnupiravir for FIP represents a crucial advancement in managing a devastating disease. By providing feline-friendly formulations such as fish- and chicken-flavored oral liquids, we offer veterinarians more tools to enhance their patients' recovery and quality of life. We are eager to see the positive effects this treatment will have on the cats and pet owners we serve."

Nicole Jacque, Co-Founder of FIP Global CATS, added, "The availability of compounded molnupiravir is a major breakthrough in FIP treatment for cats in the U.S. With proven safety and efficacy in both published and ongoing studies, molnupiravir has already shown its value in countries where it is legally available, such as in curbing the FIP outbreak in Cyprus. Importantly, it serves as a vital rescue option for cats that may have developed resistance to other antivirals. FIP Global CATS is thrilled that U.S. veterinarians and cat owners now have access to this powerful treatment, bringing us closer to making safe, effective, and affordable regulated FIP treatment the standard of care worldwide."

Wedgewood’s molnupiravir is available in dosages of 10-20 mg/kg, adhering to international veterinary research and tailored to the specific needs of feline patients. This custom approach ensures that each cat receives the best possible chance for recovery.

Wedgewood is renowned as the nation’s largest and most trusted provider of compounded veterinary medications. Its innovative home delivery platform, Blue Rabbit, enhances patient care and represents a significant leap forward in online pharmacy services. Together, Blue Rabbit and Wedgewood support more than 70,000 veterinary professionals and over one million animals each year.

FIP Global CATS is a prominent organization dedicated to combating Feline Infectious Peritonitis. It brings together veterinarians, researchers, and pet owners to provide essential support for those dealing with an FIP diagnosis. The organization focuses on empowering pet parents, advocating for safe and affordable treatments, and advancing FIP research.